Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond

Skye Bioscience (SKYE) announced that it has achieved more than 50% of targeted patient enrollment for its CBeyond Phase 2 clinical trial assessing nimacimab, a differentiated CB1 inhibitor, in patients with overweight or obesity. Skye expects to report interim data for the CBeyond Phase 2 clinical trial in Q2 2025 after this initial set of enrolled patients has completed the 26-week treatment period. “We are grateful for the amazing motivation and responsiveness shown by our study participants and clinical investigators in the assessment of this first-in-class drug candidate for weight loss. The current pace of patient enrollment may also shorten our timeline to topline data next year. We will provide a further update after reaching full enrollment,” said Puneet Arora, MD, Skye’s Chief Medical Officer. “This is a rigorous clinical trial evaluating multiple important parameters. We look forward to advancing nimacimab through this program and getting this Phase 2 data next year.”